WELLESLEY, Mass., March 27, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM) today announced that members of its executive team will participate at the 24th Annual Needham Healthcare Conference being held virtually April 7-10, 2025.
24th Annual Needham Virtual Healthcare Conference
Format: Presentation and one-on-one investor meetings
Date: April 10, 2025
Time: 8:45 a.m. ET
Webcast: Click here
About Climb Bio, Inc.
Climb Bio, Inc. is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company’s pipeline includes, budoprutug, an anti-CD19 monoclonal antibody that has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases, and CLYM116, an anti-APRIL monoclonal antibody currently in IND-enabling studies for IgA nephropathy. For more information, please visit climbbio.com.
Investors
Chris Brinzey
ICR Healthcare
This email address is being protected from spambots. You need JavaScript enabled to view it.
339-970-2843
Media
Jon Yu
ICR Healthcare
This email address is being protected from spambots. You need JavaScript enabled to view it.
475-395-5375
| Last Trade: | US$3.01 |
| Daily Volume: | 0 |
March 25, 2025 February 25, 2025 February 24, 2025 February 04, 2025 January 09, 2025 | |
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MORE
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
